D-serine for Posttraumatic Stress Disorder Treatment
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 22
- 试验地点
- 1
- 主要终点
- CAPS scores
研究概览
简要总结
The aim of this study is to asses the effects of the NMDA receptor full agonist D-serine while used as adjuvant treatment for individuals suffering from chronic posttraumatic stress disorder (PTSD). Dysfunction of neurotransmission mediated at NMDA receptor plays a cardinal role in the pathophysiology of PTSD and PTSD patients typically suffer from cognitive dysfunctions and avoidance& depressive symptomatology that may be mediated by NMDA receptor function deficits.
Thus, enhancement of NMDA activity by using D-serine may be beneficial in the treatment of PTSD. The study design involves two 6 week periods during which the participants will be randomly assigned to receive treatment with D-serine (~2g /dy)and placebo. This design allows each participant the opportunity to respond to the experimental treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 25 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Chronic PTSD (DSM-IV diagnosis)
排除标准
- •Other psychiatric diagnosis
- •Substance abuse
- •Unstable medical condition
研究组 & 干预措施
1
Adjuvant 6 weeks treatment with placebo (~2g /day)
干预措施: D-serine (~2g /day) (Drug)
2
Adjuvant 6 weeks treatment with D-serine (~2g /day)
干预措施: D-serine (~2g /day) (Drug)
结局指标
主要结局
CAPS scores
时间窗: 6 week treatment
次要结局
未报告次要终点
研究者
Heresco-Levi Uriel
Principal Investigator
Herzog Hospital